Asuragen to Provide GLP Laboratory Testing Services to a Biotechnology Organization

News May 30, 2007

Asuragen, Inc. has announced that it was selected to provide GLP compliant laboratory testing to assist in gene expression studies being conducted by Millennium Pharmaceuticals of Cambridge, MA.

Asuragen, a cGMP/GLP facility, is dedicated to helping the scientific community and industry to discover and develop new products for the advancement of cancer research and companion diagnostics.

“We are committed to applying our RNA expertise to produce the data quality required in clinical studies with organizations such as Millennium and believe that research like this may enable companion diagnostics and support the value of personalized medicine,” commented Scott Hunicke-Smith, V.P. and General Manager of Asuragen Services.

Schizophrenia: Hippocampus Drastically Shrinks in Adolescents With Psychotic Symptoms

News

Schizophrenia may be related to genetic abnormalities of chromosome 22, known as 22q11 deletion syndrome. However, not everyone who has the syndrome necessarily develops psychotic symptoms. So, what triggers the illness? An 18-year-long study provides some answers.

Mutation Discovery Could Help Treat Children With Developmental Disorders

News

Analysis of 31,000 parent-child trios yielded more than 45,000 de novo mutations (DNMs). Researchers developed an improved method to test for the enrichment (over-representation) of damaging DNMs in individual genes and found 307 significantly enriched genes, 49 of which are novel.

Pre-Conception Risk Evaluation for Recurrence of Developmental Disorder in Future Pregnancies

News

Researchers present the PREGCARE study, which aims to provide healthy couples who have a child affected by a developmental disorder with a personalised pre-conception risk evaluation, at the European Society of Human Genetics annual conference.

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free